Survey of diagnostic testing for respiratory syncytial virus (RSV) in adults: Infectious disease physician practices and implications for burden estimates

2018 ◽  
Vol 92 (3) ◽  
pp. 206-209 ◽  
Author(s):  
Kristen E. Allen ◽  
Susan E. Beekmann ◽  
Philip Polgreen ◽  
Sarah Poser ◽  
Jeanette St. Pierre ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Respiratory Syncytial Virus ◽  
Diagnostic Testing ◽  
Infectious Disease Physician ◽  
Physician Practices ◽  
Syncytial Virus

scholarly journals 1718. Respiratory Syncytial Virus (RSV) Surveillance in the Department of Veterans Affairs (VA), 2010-2018

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S843-S843
Author(s):  
Cynthia Lucero-Obusan ◽  
Patricia Schirmer ◽  
Gina Oda ◽  
Mark Holodniy
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Infections ◽  
Diagnostic Testing ◽  
Fold Increase ◽  
Respiratory Illness ◽  
Veterans Affairs ◽  
Department Of Veterans Affairs ◽  
Management And Development ◽  
Syncytial Virus ◽  
National Trends

Abstract Background Respiratory Syncytial Virus (RSV) is an increasingly recognized cause of acute respiratory illness in older adults, leading to an estimated 177,000 hospitalizations and 14,000 deaths each year in the US. In adult populations, diagnostic testing for RSV has historically been underutilized. Herein, we examine national trends in RSV testing and infection across the Veterans Affairs (VA) healthcare system. Methods Electronic RSV laboratory testing results, ICD-coded hospitalizations and outpatient encounters were obtained from VA’s Praedico Surveillance System (1/1/2010-12/31/2018). Patients were reviewed for positive results, repeat testing, and demographics. Antibody tests were excluded. Results A total of 102,251 RSV results were included. Overall, 4,372 (4.3%) specimens from 4,263 unique individuals were positive with a median age of 67 years (range 0-101) and 90% were male. 1,511 individuals (35.4%) also had an RSV-coded hospitalization. RSV type was specified for only 7.8% of positives (Table). During 2010-2018 there were 2,522 RSV-coded hospitalizations (median length of stay = 4 days) among 2,444 unique individuals, which included 413 ICU stays (16.4%) and 98 deaths (3.9%) during the RSV-coded hospitalization. Approximately 78% of RSV-coded hospitalizations within VA (excluding all non-VA hospitalizations) had a documented positive test result. A greater than 15-fold increase in RSV tests performed, hospitalizations and outpatient encounters was observed from 2010-2018, although the percent testing positive remained relatively stable (Figure, Table). Figure. Testing for Respiratory Syncytial Virus (RSV), Department of Veterans Affairs, 2010-2018. Table. Select RSV Surveillance Metrics, Department of Veterans Affairs, 2010-2018 Conclusion RSV testing and identification of patients with RSV infection increased dramatically during the time period analyzed, likely due to increased availability of PCR-based multi-pathogen panels and duplex assays. While the percentage of tests positive for RSV remained relatively stable, the rise in coded hospitalizations may be due to increased testing for RSV among hospitalized Veterans with severe respiratory infections. These surveillance data may allow for further characterization of RSV disease burden estimates which can help inform clinical management and development of interventions for adults, such as vaccines and antiviral therapies. Disclosures All Authors: No reported disclosures

Case Studies in Infectious Disease: Respiratory syncytial virus

2009 ◽  
Author(s):  
Peter Lydyard ◽  
Michael Cole ◽  
John Holton ◽  
Will Irving ◽  
Nino Porakishvili ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Respiratory Syncytial Virus ◽  
Case Studies ◽  
Syncytial Virus

The Quest for an Efficacious Antiviral for Respiratory Syncytial Virus

2002 ◽  
Vol 13 (6) ◽  
pp. 325-344 ◽  
Author(s):  
Paul F Torrence ◽  
Linda D Powell
Keyword(s):  
Infectious Disease ◽  
Respiratory Syncytial Virus ◽  
Mechanism Of Action ◽  
Therapeutic Agent ◽  
The Elderly ◽  
Fusion Process ◽  
Viral Fusion ◽  
Antisense Approach ◽  
Syncytial Virus ◽  
New Hypothesis

Respiratory syncytial virus (RSV) continues as an emerging infectious disease not only among infants and children, but also for the immune-suppressed, hospitalized and the elderly. To date, ribavirin (Virazole) remains the only therapeutic agent approved for the treatment of RSV. The prophylactic administration of palivizumab is problematic and costly. The quest for an efficacious RSV antiviral has produced a greater understanding of the viral fusion process, a new hypothesis for the mechanism of action of ribavirin, and a promising antisense strategy combining the 2′-5′ oligoadenylate antisense (2–5′A-antisense) approach and RSV genomics.

scholarly journals Using linked health data in international comparisons of infectious disease burden

2018 ◽  
Vol 3 (4) ◽  
Author(s):  
Rachel Reeves
Keyword(s):  
Infectious Disease ◽  
Respiratory Syncytial Virus ◽  
Infectious Diseases ◽  
Disease Burden ◽  
International Comparisons ◽  
Population Level ◽  
Health Data ◽  
Routinely Collected Data ◽  
Syncytial Virus ◽  
International Comparative

Linking population-level health databases – such as those on hospital admissions, GP consultations, prescriptions, maternal and perinatal data, and laboratory data – provides great opportunities to explore the epidemiology and burden of infectious diseases. Furthermore, comparing the epidemiology and burden of infectious diseases on an international scale is crucial in designing and implementing national and global prevention and control measures. However, substantial differences between countries in national health systems (including thresholds for hospital admission), as well as varying availability and quality of routinely collected data, can pose challenges when using linked population-level health databases to compare estimates of infectious disease burden between countries. This session aims to highlight and discuss the opportunities and challenges of international comparisons of infectious disease burden using linked population-level health data. This session will facilitate discussion of the methodological, ethical and resource challenges when using linked health data to produce internationally comparable estimates of the burden of infectious diseases. We will use as an example the ongoing work of the REspiratory Syncytial virus Consortium in Europe (RESCEU) – a large-scale collaborative project producing evidence to inform policymaking and regulatory decisions on novel respiratory syncytial virus (RSV) vaccines and therapeutics. The RESCEU project involves at least seven European countries each using linked routinely collected health data to produce national estimates of the health and economic burden of RSV, by age and risk group, for comparison. The results will highlight target populations for future vaccines and therapeutics, and provide a baseline estimate of the pre-vaccine era burden of disease that can be used to measure future vaccine impact. We will share the challenges faced in the RESCEU project with regards to using linked health data in international comparative work. We will then discuss, with relevance to other ongoing or future projects, how these challenges may be overcome. This session will generate ideas for procedures and tools for international comparative work using routinely collected data to investigate infectious diseases. This session will provide the opportunity to network with other researchers working in this area. We aim to facilitate the generation and dissemination of ideas for current and future projects, and therefore this session is likely to identify areas for potential future international collaborative work.

scholarly journals 1182. Clinical Outcomes of Hospital-Associated Respiratory Virus Infections

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S423-S424
Author(s):  
Joshua G Petrie ◽  
Adam S Lauring ◽  
Keith S Kaye
Keyword(s):  
Respiratory Syncytial Virus ◽  
Clinical Outcomes ◽  
Influenza A ◽  
Respiratory Virus ◽  
Diagnostic Testing ◽  
Direct Result ◽  
Molecular Diagnostic ◽  
Virus Infections ◽  
Syncytial Virus ◽  
Respiratory Virus Infections

Abstract Background Influenza and respiratory syncytial virus (RSV) are recognized as important causes of hospital-acquired infection. Increased use of multiplex molecular diagnostic testing is shedding light on the incidence of other hospital-associated respiratory virus infections (HA-RVI). However, the incidence and clinical impact of HA-RVI are not well understood. Methods We identified hospitalized patients admitted between July 1, 2017 and June 30, 2018 who were clinically tested to diagnose respiratory virus infections. HA-RVI were defined as respiratory virus positivity beginning more than 48 hours after hospital admission. The clinical outcomes of HA-RVI were compared with respiratory virus infections that were not considered hospital-associated (non-HA-RVI). Results Respiratory virus testing was performed on 4,690 individuals during 5,942 inpatient encounters. At least 1 virus was identified in 1,871 (31%) encounters, and 229 (12%) were defined as HA-RVI (median hours from admission to positivity [IQR]: 154 [79, 308]). Among the patients with a respiratory virus infection, 56% were adults, 52% were male, 77% were non-Hispanic white, and the median Charlson score was 2 (IQR: 1, (4); HA-RVI patients were more likely to be male (59% vs. 51%, P = 0.01) and had higher median Charlson scores (3 vs. 2, P < 0.001). All 14 respiratory viruses in the diagnostic panel were positive for at least one HA-RVI (Figure 1), but rhino/enterovirus (99), influenza A (27), human metapneumovirus (22) and respiratory syncytial virus (20) were most common. Compared with non-HA-RVI patients, those with HA-RVI had longer post-infection lengths of stay (median: 9 vs. 4 days, P < 0.001) and were more likely to die during hospitalization (odds ratio [95% confidence interval]: 3.4 [2.0, 5.7]) (Table 1). Conclusion A substantial number of HA-RVI were identified during the 2017–2018 respiratory virus season, and they were associated with a striking number of severe outcomes. More in depth analyses are required to determine whether severe outcomes are a direct result of HA-RVI or whether HA-RVI are more common in critically ill patients and serve as a marker for severe morbidity. A broader understanding of HA-RVI transmission and prevention strategies is needed. Disclosures All authors: No reported disclosures.

Characteristics of Respiratory Syncytial Virus isolated from Acute Respiratory Infectious Disease in Busan

2016 ◽  
Vol 46 (3) ◽  
pp. 173 ◽  
Author(s):  
Su-Jeong Hwang ◽  
Dong-Ju Park ◽  
Pyeung-Tae Gu ◽  
Hee-Soo Koo ◽  
Mi-Ok Lee
Keyword(s):  
Infectious Disease ◽  
Respiratory Syncytial Virus ◽  
Syncytial Virus

scholarly journals Delayed Diagnosis of Respiratory Syncytial Virus Infections in Hospitalized Adults: Individual Patient Data, Record Review Analysis and Physician Survey in the United States

2019 ◽  
Vol 220 (6) ◽  
pp. 969-979 ◽  
Author(s):  
Nelson Lee ◽  
Edward E Walsh ◽  
Ian Sander ◽  
Robert Stolper ◽  
Jessica Zakar ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Individual Patient Data ◽  
Respiratory Infections ◽  
Diagnostic Testing ◽  
Delayed Diagnosis ◽  
Antibiotic Use ◽  
The United States ◽  
Patient Data ◽  
Diagnostic Strategies ◽  
Syncytial Virus

AbstractBackgroundDespite the prevalence of respiratory syncytial virus (RSV) in adults hospitalized with acute respiratory infections, guidelines for the diagnosis and management of RSV have not been established. This analysis evaluated the role and timeliness of RSV diagnostic testing and its potential impact on clinical outcomes.MethodsWe analyzed individual patient data from hospitalized adults with confirmed RSV infections during 2 North American RSV seasons. Participating physicians reported clinical, virologic diagnosis, and outcome variables using a standardized online case form.ResultsAcross 32 US states, 132 physicians reported 379 RSV cases. Polymerase chain reaction–based diagnostics were the most common type of test ordered (94.2%) with <5% ordered specifically to diagnose RSV. Most tests (67.6%) were ordered in hospital wards or intensive care units. Overall, 47.4%, 30.9%, and 21.7% of patients had RSV diagnosed <12, 12‒24, and >24 hours after hospital admission, respectively. Later diagnosis was associated with longer hospital stays (n = 145; R = +0.191; P < .05) and greater antibiotic use.ConclusionDiagnosis of RSV infection in hospitalized adults is often delayed, which may affect clinical management and outcomes. Our findings indicate the need to improve the diagnostic strategies in this patient population.

scholarly journals Evaluation of the ImmuView RSV Test for Rapid Detection of Respiratory Syncytial Virus in Adult Patients with Influenza-Like Symptoms

2021 ◽  
Author(s):  
E. Larsson ◽  
S. Johansson ◽  
O. Frøbert ◽  
A. Nordenskjöld ◽  
S. Athlin
Keyword(s):  
Respiratory Syncytial Virus ◽  
Hospital Stay ◽  
Rapid Detection ◽  
Diagnostic Testing ◽  
Antibiotic Usage ◽  
Adult Patients ◽  
Nosocomial Transmission ◽  
The Novel ◽  
Rsv Infection ◽  
Syncytial Virus

By timely RSV diagnosis among patients with influenza-like symptoms, especially when influenza diagnostics turn negative, it is possible to prevent unnecessary antibiotic usage as well as reduce diagnostic testing, nosocomial transmission, and hospital stay. Previous rapid RSV tests have demonstrated poor sensitivity in adults, and we could demonstrate that the novel ImmuView RSV test similarly showed limited value for diagnosing RSV infection in adult patients.

Sign in / Sign up

Export Citation Format

Share Document